ADOCIA Aktie [WKN DE: A1JTC2 / ISIN: FR0011184241]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu ADOCIA

16.12.15		Adocia Announces Its Financial Calendar for 2016 (Businesswire)
15.12.15		Adocia to Hold Conference Call For Investors to Provide 2015 Annual Business Update and Perspectives For 2016 (Businesswire)
11.12.15		Adocia and Lilly report positive results of a pilot bioequivalence study comparing BioChaperone Lispro U200 to BioChaperone Lispro U100 (Businesswire)
25.11.15		Adocia announces positive Phase 1b results of BioChaperone® Combo in patients with type 2 diabetes (Businesswire)
04.11.15		Adocia Announces Positive Phase 1b Results on the Post-Meal Effect of BioChaperone® Combo in Patients with Type 1 Diabetes (Businesswire)
13.10.15		ADOCIA Reports Third Quarter 2015 Financial Results (Businesswire)
06.10.15		Adocia and Lilly Initiate a Phase 1b Study Evaluating Ultra-Rapid BioChaperone Lispro in Patients with Type 1 Diabetes Using Insulin Pump Therapy (Businesswire)
05.10.15		Adocia to hold an extraordinary shareholders’ meeting on November 12, 2015 in Lyon (Businesswire)
30.09.15		Adocia and Lilly initiate a new Phase 1b study of repeat administration of ultra-rapid BioChaperone Lispro in patients with type 2 diabetes (Businesswire)
17.09.15		ADOCIA: additional contribution to the liquidity agreement (Businesswire)
27.08.15		Adocia and Lilly Initiate New Phase 1b Study of Repeated Administration of Ultra-Rapid BioChaperone Lispro in Patients with Type 1 Diabetes (Businesswire)
24.08.15		Adocia Initiates a Clinical Study on a High Concentration Formulation of the Ultra-Rapid Insulin BioChaperone Lispro (Businesswire)
21.07.15		Adocia Presents Financial Results for the First Half of 2015 Highlighting Strong Growth (Businesswire)
10.07.15		Adocia Initiates Two Clinical Studies on Its Combination of Long-Acting Insulin Glargine and Fast-Acting Insulin Lispro, BioChaperone® Combo (Businesswire)
26.06.15		Adocia and Lilly report positive Phase 1b topline results on the post-meal effect of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes (Businesswire)
15.06.15		Adocia is Now Integrated into the CAC Mid 60 and SBF 120 Indices (Businesswire)
28.05.15		Adocia to Present Positive Clinical Results for BioChaperone® Lispro at the American Diabetes Association 75th Scientific Sessions on June 6th 2015 (Businesswire)
26.05.15		Adocia to Present at the Jefferies 2015 Global Healthcare Conference in New-York City (USA) (Businesswire)
04.05.15		Adocia Announces the Release of Its Reference Document, Containing the Annual Financial Report, for the Year 2014 (Businesswire)
29.04.15		Adocia is Now Integrated into the EnterNext Tech 40 Index (Businesswire)
20.04.15		Adocia to Hold Its Annual Shareholders’ Meeting on May 27, 2015 in Lyon (Businesswire)
14.04.15		Adocia Announces First Quarter 2015 Results (Businesswire)
27.03.15		Adocia Successfully Raises Approx. €32m from Healthcare Specialist Investors (Businesswire)
26.03.15		Adocia to Raise Capital in a Private Placement of New Shares (Businesswire)
16.03.15		Adocia Will Present Its 2014 Annual Results and Its Perspectives of Growth During a Conference Call : Tuesday March 17, 2015 at 6:00 PM (CET) (Businesswire)
10.03.15		Adocia Reports a Strengthened Cash Position and Intensifies Clinical Development (Businesswire)
05.03.15		Adocia Opens a Subsidiary in the USA and is Pleased to Appoint Simon Bruce, MD and Stephen Daly (Businesswire)
17.02.15		ADOCIA: Annual Revenue and Net Cash Position for 2014 (Businesswire)
10.02.15		Adocia: Modification of the Means Allocated to the Liquidity Agreement (Businesswire)
05.02.15		Adocia Reports Positive Results from Phase IIa Clinical Study of Fast-Acting Human Insulin, HinsBet® (Businesswire)
20.01.15		Adocia Initiates a Clinical Study on the Post-Meal Effect of Ultra-Rapid BioChaperone Lispro Insulin Formulation (Businesswire)
09.01.15		Half Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets (Businesswire)
29.12.14		Adocia Announces Its Financial Calendar for 2015 (Businesswire)
22.12.14		ADOCIA: Shareholder Newsletter (Businesswire)
19.12.14		Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology (Businesswire)
16.10.14		ADOCIA Announces Third-Quarter Financial 2014 Results (Businesswire)
30.09.14		ADOCIA Wins Frost & Sullivan 2014 Technology Innovation Leadership Award in the Therapeutic Proteins Industry (Businesswire)
09.09.14		Adocia Reports Positive Preliminary Results from Dose Response Clinical Study of Ultra-fast acting BioChaperone® Lispro U100 in Patients with Type 1 Diabetes (Businesswire)
25.08.14		Adocia Launches Phase III Clinical Study in India Of Treatment for Diabetic Foot Ulcer (Businesswire)
24.07.14		Adocia Reports Operational and Financial Results for the First Half of 2014 (Businesswire)
10.07.14		Half Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets (Businesswire)
09.07.14		Adocia Announces Approval to Start a Phase IIa Clinical Study of HinsBet®, its Fast-acting Human Insulin, in Type 1 Diabetes (Businesswire)
10.06.14		Adocia Announces Positive Preclinical Results for a Concentrated Ultra-Fast insulin, BioChaperone® Lispro U300 (Businesswire)
04.06.14		Adocia to Present Successful Clinical Results for BioChaperone® Lispro and BioChaperone Combo at the American Diabetes Association 74th Scientific Sessions on June 15th 2014 (Businesswire)
27.05.14		Adocia Initiates ADR program (American Deposit Receipt) in the United States (Businesswire)
20.05.14		Adocia Initiates a Dose-Response Phase IIa Clinical Study of Ultra-fast Acting BioChaperone® Lispro (Businesswire)
19.05.14		Adocia Announces the Signature of a Liquidity Agreement with Kepler Capital Markets SA (Businesswire)
17.04.14		ADOCIA Announces First-Quarter 2014 Results (Businesswire)
09.04.14		Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone® Lispro (Businesswire)
25.03.14		Adocia announces financial results for 2013 (Businesswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Krypto-Influencer prognostiziert für 2025 gewaltige Rally beim Dogecoin

Solana Kurs-Prognose: 300 US-Dollar noch im Januar?

Krypto-News: Während der Bitcoin konsolidiert pumpen Solana, Ripple und der Dogecoin

Hochstufung durch Exane BNP Paribas treibt UBS-Aktie an

Zinspolitik 2025: EZB plant Senkungen - wie schnell kommen sie?

Lilium-Aktie im Rallymodus: Lilium erhält Finanzspritze von Geldgeber

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	05.01.2025 09:21
Kaufwert:	EUR
	Hinzufügen Speichern